Select Language
IL-13
IL-13 Overview
| English Name | Interleukin-13 | Approved Drugs | 4 |
| Drugs in Clinical Trials | 26 | Target Synonym | Interleukin-13，IL13，Interleukin 13，IL-13，Bronchial Hyperresponsiveness-1 (Bronchial Asthma)，Allergic Rhinitis，P600，NC30，MGC116789，MGC116788，BHR1，MGC116786，ALRH |
| Highest Development Stage | Approved | ||
| English Name | Interleukin-13 |
| Target Synonym | Interleukin-13，IL13，Interleukin 13，IL-13，Bronchial Hyperresponsiveness-1 (Bronchial Asthma)，Allergic Rhinitis，P600，NC30，MGC116789，MGC116788，BHR1，MGC116786，ALRH |
| Approved Drugs | 4 |
| Drugs in Clinical Trials | 26 |
| Highest Development Stage | Approved |
IL-13 Product List
- Product Category
Protein (11)Kits (3)
- Product Status
Launched (13)In Research (1)
- Species
Human (8)Canine (1)Mouse (2)Cynomolgus (3)
- Tag
Fc Tag (2)His Tag & Avi Tag (3)His Tag (5)GST Tag (1)- (3)
- Conjugate
Unconjugated (8)Biotin-labeled (3)- (3)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT IL3-H5256 |  Human | HEK293 | Human IL-13 Protein, Fc Tag, low endotoxin (MALS verified) |  |  |  |
HOT IL3-H52H3 | Human | HEK293 | Human IL-13 Protein, His Tag, premium grade (cell activity verified) |  | | |
HOT IL3-H82E5 | Human | HEK293 | Biotinylated Human IL-13 Protein, His,Avitag™ (MALS verified) |  | | |
HOT IL3-C5249 |  Cynomolgus | HEK293 | Cynomolgus IL-13 Protein, His Tag, low endotoxin (MALS verified) |  | | |
CEA-C013 | Human | - | Human IL-13 ELISA Kit | |||
FCSh-029 | Human | - | Human IL-13 Detection Kit (Flow Cytometry Bead Assay) | |||
FRT-P038 | Human | - | Human IL-13 / IL-13 R alpha 1 Inhibitor Screening Kit (TR-FRET) | |||
IL3-H5259 | Human | HEK293 | Human IL-13 (E31K) Protein, Fc Tag (MALS verified) |  | | |
IL3-H52G3 | Human | HEK293 | Human IL-13 Protein, GST Tag |  | | |
IL3-M5249 |  Mouse | HEK293 | Mouse IL-13 Protein, His Tag (MALS verified) |  | | |
Total: 14
- 1
- 2
IL-13 Background
Interleukin 13 (IL13) is also known as ALRH, BHR1and P600, is a single-chain glycosylated polypeptide, and is a cytokine critical in regulating inflammatory and immune responses. IL13 is secreted by many cell types, but especially by T helper type 2 (Th2) cells. IL-13 induces its effects through a multi-subunit receptor that includes the alpha chain of the IL-4 receptor (IL-4Rα) and at least one of two known IL-13-specific binding chains. The functions of IL-13 overlap considerably with those of IL-4, especially with regard to changes induced on hematopoietic cells, but these effects are probably less important given the more potent role of IL-4. IL-13 induces matrix metalloproteinases (MMPs) as part of a mechanism that protects against excessive allergic inflammation that predisposes to asphyxiation. IL-13 induces many features of allergic lung disease, including airway hyperresponsiveness, goblet cell metaplasia and mucus hypersecretion, which all contribute to airway obstruction.
IL-13 Synonyms
IL13,ALRH,BHR1,MGC116786,MGC116788,MGC116789,P600,Interleukin-13
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Dupilumab biosimilar (Jingxing Pharmaceutical) | GS101; GS-101; GS-101 (Jingxing Pharmaceutical) | Phase 3 Clinical | Jiangsu Jingxing Pharmaceutical Technology Co Ltd | Dermatitis, Atopic | Details |
| Dupilumab biosimilar (Qilu Pharma) | QL2108; QL-2108 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Asthma; Dermatitis, Atopic; Prurigo | Details |
| Tilrekimig | PF-07275315 | Phase 3 Clinical | Pfizer Inc | Asthma; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive | Details |
| Lunsekimig | SAR-443765 | Phase 3 Clinical | Sanofi | Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Inflammation; Pulmonary Disease, Chronic Obstructive | Details |
| Cendakimab | RPC-4046; ABT-308; CC-93538 | Phase 3 Clinical | Abbott Laboratories | Asthma; Dermatitis, Atopic; Eczema; Eosinophilic Esophagitis; Eosinophilic gastroenteritis (EG) | Details |
| Eblasakimab | MK-6105; ASLAN-004; CSL-334 | Phase 2 Clinical | Csl Ltd, Merck Sharp & Dohme Corp | Dermatitis, Atopic; Hypersensitivity | Details |
| Dectrekumab/VAK-694 | QBX-258 | Phase 2 Clinical | Novartis Pharma Ag | Asthma; Lymphedema | Details |
| JNJ-5939 | JNJ-5939; NM-26; NM26-2198; JNJ-95475939 | Phase 2 Clinical | Numab Therapeutics Ag | Dermatitis, Atopic; Inflammation | Details |
| APG-279 | APG279; APG-990/APG777 | Phase 2 Clinical | Apogee Therapeutics Inc | Dermatitis, Atopic | Details |
| CM-512 | CM512; CM-512 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Asthma; Bronchiectasis; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Rhinitis, Allergic; Sinusitis | Details |
| Zumilokibart | PR004; PR-004; APG-777; APG 777; APG777 | Phase 2 Clinical | Apogee Therapeutics Inc | Asthma; Dermatitis, Atopic | Details |
| Ompekimig | PF-07264660 | Phase 2 Clinical | Pfizer Inc | Dermatitis, Atopic | Details |
| SC-CAR4BRAIN | Phase 1 Clinical | Seattle Children'S Hospital | Carcinoma; Carcinoma, Hepatocellular; Central Nervous System Neoplasms; Desmoplastic Small Round Cell Tumor; Diffuse Intrinsic Pontine Glioma; Diffuse midline glioma; Endodermal Sinus Tumor; Hepatoblastoma; Liposarcoma; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neurofibrosarcoma; Osteosarcoma; Retinoblastoma; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Clear Cell; Sarcoma, Ewing; Sarcoma, Synovial; Solid tumours; Wilms Tumor | Details | |
| Dupixent biosimilar (Chong Kun Dang Pharmaceutical) | CKD-706 | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Dermatitis, Atopic | Details |
| Dupilumab biosimilar (China Resources Biopharma) | Phase 1 Clinical | China Resources Biopharmaceutical Co Ltd | Dermatitis, Atopic | Details | |
| APG273 | APG273; APG-273 | Phase 1 Clinical | Apogee Therapeutics Inc | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| Dupilumab biosimilar (Jiangsu Jingxing Pharma) | Phase 1 Clinical | Jiangsu Jingxing Pharmaceutical Technology Co Ltd | Dermatitis, Atopic | Details | |
| Dupilumab biosimilar (Chengdu Kanghong) | KH-816; KH816 | Phase 1 Clinical | Chengdu Kanghong Biotechnologies Co Ltd | Dermatitis, Atopic | Details |
| WIN-027 | QX027N; QX-027-N; WIN027; WIN-027 | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Asthma; Dermatitis, Atopic | Details |
| Dupilumab biosimilar (Jushi Biopharma) | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Dermatitis, Atopic | Details | |
| ATTO-3712 | ATTO-3712 | Phase 1 Clinical | Attovia Therapeutics Inc | Dermatitis, Atopic; Pruritus | Details |
| GB-7624 | GB-7624 | Phase 1 Clinical | Generate Biomedicines Inc | Dermatitis, Atopic | Details |
| ZL-1503 | ZL-1503 | Phase 1 Clinical | Zai Lab Ltd | Dermatitis, Atopic | Details |
| SAR-444765 | SAR444765; SAR-444765 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| Dupilumab biosimilar (Bio-Thera Solutions) | BAT2406; BAT-2406 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Asthma; Dermatitis, Atopic; Eosinophilic Esophagitis; Nasal Polyps; Prurigo Nodularis; Sinusitis | Details |
| SAR-443726 | SAR-443726 | Phase 1 Clinical | Sanofi | Dermatitis, Atopic | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Dupilumab | REGN-668; SAR-231893 | Approved | Regeneron Pharmaceuticals Inc, Sanofi | Dupixent, 达必妥 | United States | Dermatitis, Atopic | Regeneron Pharmaceuticals Inc | 2017-03-28 | Allergic Fungal Rhinosinusitis; Alopecia Areata; Angioedema; Aspergillosis, Allergic Bronchopulmonary; Asthma; Asthma, Aspirin-Induced; Chronic Urticaria; Colitis, Ulcerative; Conjunctivitis, Allergic; Coronavirus Disease 2019 (COVID-19); Dermatitis; Dermatitis, Atopic; Eczema; Eosinophilic Esophagitis; Eosinophilic gastroenteritis (EG); Genetic Diseases, Inborn; Hypereosinophilic Syndrome; Hypersensitivity; Hypersensitivity, Immediate; Keloid; Keratoconjunctivitis; Lichenoid Eruptions; Milk Hypersensitivity; Nasal Polyps; Nephrotic Syndrome; Neurodermatitis; Paranasal Sinus Diseases; Peanut Hypersensitivity; Pemphigoid, Bullous; Prostatic Neoplasms; Prurigo; Prurigo Nodularis; Pruritus; Pulmonary Disease, Chronic Obstructive; Respiration Disorders; Respiratory Sounds; Respiratory Tract Diseases; Rhinitis, Allergic; Scleroderma, Localized; Sinusitis; Skin Diseases; Skin Diseases, Eczematous; Sleep Apnea Syndromes; Urticaria | Details |
| Berdazimer sodium | NVN-1000-SB-206-Novan; SB-206; MAP3-NONOate - SB-206; NVN1000-SB206; SB-019; NI-MC101; SB-207; SB-208; SB-204; SB-414 | Approved | University Of North Carolina At Chapel Hill | KINSOLUSTM, Zelsuvmi, ZELSUVMI | United States | Molluscum Contagiosum | Lnhc Inc | 2024-01-05 | Acne Vulgaris; Condylomata Acuminata; Dermatitis, Atopic; Molluscum Contagiosum; Psoriasis; Tinea Pedis | Details |
| Lebrikizumab | RO 5490255; TNX 650; Anti-IL-13; TNX-650; RG-3637; RO-5490255; RO-4909832; PRO-301444; DRM-06; MILR-1444A; R-3637; DRM 06; LY 3650150; MILR1444A; MILR1444Ab; RG 3637 | Approved | Tanox Inc | EBGLYSS | EU | Dermatitis, Atopic | Almirall Sa | 2023-11-16 | Alzheimer Disease; Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis; Dermatitis, Atopic; Eczema; Hodgkin Disease; Idiopathic Pulmonary Fibrosis; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Rhinitis, Allergic; Sinusitis; Skin Diseases; Skin Diseases, Genetic | Details |
| Tralokinumab | BAK-502G9; CAT-354 | Approved | Medimmune Llc | Adtralza, ADBRY | EU | Dermatitis, Atopic | Leo Pharma A/S | 2021-06-17 | Asthma; Colitis, Ulcerative; Dermatitis, Atopic; Eczema; Idiopathic Pulmonary Fibrosis | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to: